Omnix Medical

On 9-10 September, the five PEPTAMR consortium partners came together in Athens, Greece, for the first time. The productive two-day kickoff meeting marked the beginning of an exciting three-year collaboration. PEPTAMR addresses the Horizon Europe call for

Celebrating Israeli excellence and 30 years of research and innovation partnership between Israel and Europe.Omnix Medical was honoured to take part in a celebration at the official residence of Israeli President Isaac Herzog, recognising Israeli excellen

- EUR 8M grant supports the late-stage clinical development of Omnix's antimicrobial OMN6 - Leading European partners join forces to advance OMN6 for the treatment of life-threatening hospital-acquired infections JERUSALEM, Israel, July 13, 2026 - Omnix M

PRN_FinancialWrapper

- Novel mechanism of action based on the direct physical elimination of pathogenic bacteria- First-in-class treatment of life-threatening, drug-resistant Acinetobacter baumannii infections advancing toward Phase II clinical proof-of-concept JERUSALEM, Isr

- Existing and new investors joining forces to support the accelerated development of Omnixs novel, first-in-class antimicrobials pipeline - Funding underlines urgent global need for novel, resistance-proof antimicrobials JERUSALEM, Israel, October 15, 20

PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / November 6, 2025 / Omnix Medical Ltd., P.C. ("Omnix Medical") and Prevail Partners, LLC ("Prevail Partners") join in a strategic partnership that will efficiently and economically drive the clinical advanceme

-- Existing and new investors joining forces to support the accelerated development of Omnixs novel, first-in-class antimicrobials pipeline

Omnix Medical tested its novel antimicrobial peptide, OMN51, on clinical isolates of multi-drug-resistant Pseudomonas aeruginosa collected from cystic fibrosis patients, in collaboration with Beilinson - Rabin Medical Center. The results demonstrated rapi